Pharmaceutical

CVS Health enters biosimilar fray with launch of new subsidiary

The newly-launched business, called Corvardis, is already targeting the Humira biosimilar landscape with Hyrimoz via a planned Sandoz-partnered launch in Q1 2024.

Aug 24, 2023 - 20:00
CVS Health enters biosimilar fray with launch of new subsidiary
The newly-launched business, called Corvardis, is already targeting the Humira biosimilar landscape with Hyrimoz via a planned Sandoz-partnered launch in Q1 2024.
Read the original article

Tags:

Previous Article

How the first Native Hawaiian psychiatrist set a course for diversifying medicine

Next Article

US Elections: Vivek Ramaswamy makes brazen debate debut

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Insurance companies are forcing psychiatrists like me to stop accepting their coverage

Opinion: Insurance companies are forcing psychiatrists ...

Jan 4, 2024

STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages

STAT+: Pharmalittle: Novo faces patent challenge on Weg...

Oct 6, 2023

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s ...

Apr 27, 2023